

ASX RELEASE

Volpara Quarterly Results and Investor Webinar Notification

Wellington, NZ, 19 April 2023: [Volpara Health Technologies](#) (“Volpara,” “the Group,” or “the Company”; ASX: VHT), a global leader in software for the early detection and prevention of breast cancer, will be hosting an investor webinar on **Friday 28th April 2023** at 9:00am AEST (Sydney/Melbourne), 11:00am NZST (Auckland/Wellington) to update shareholders on its Q4 financial results.

The call will be hosted by Teri Thomas, Managing Director, Craig Hadfield, Chief Financial Officer and Jill Spear, Executive Vice President of Sales and Marketing

Webinar details

Date: Friday 28th April 2023
Time: 9:00am AEST (Sydney/Melbourne), 11:00am NZST (Auckland/Wellington)
To register: https://us02web.zoom.us/webinar/register/WN_q-QGThQL6sZ-uuwam1xQ
Dial in details: Will be provided to you upon registration

Participants will be able to submit questions during the webinar via a written Q&A facility displayed at the bottom of the webinar screen or can submit them in advance to hhowlett@we-worldwide.com

Authorisation & Additional Information

This announcement was authorised by the Chief Executive Officer and Managing Director of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Corporate Enquiries

Teri Thomas, CEO & MD
Volpara Health Technologies
Teri.thomas@volparahealth.com
t: +64 4 499 6029

Investor Relations

Hannah Howlett
WE Communications
hhowlett@we-worldwide.com
t: +61 4 5064 8064

About Volpara Health Technologies Limited (ASX: VHT)

Volpara Health Technologies makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,000 technologists, impacting nearly 15 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A\$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand

For more information, visit www.volparahealth.com.